Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | KDM5A | P29375 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.35 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3877781 | 1.00 | SIGMAR1 (0.38) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL8944630 | 0.90 | — | — | |
| SCHEMBL7458143 | 0.89 | SIGMAR1 (0.54) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL7452816 | 0.89 | SIGMAR1 (0.54) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL17027405 | 0.89 | SIGMAR1 (0.54) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL7457427 | 0.89 | SIGMAR1 (0.54) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL7458663 | 0.89 | SIGMAR1 (0.54) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL98103 | 0.89 | SIGMAR1 (0.54) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL7457536 | 0.89 | SIGMAR1 (0.54) | SIGMAR1KDM5AKDM4CPHF8KDM2A | |
| SCHEMBL7453118 | 0.89 | SIGMAR1 (0.54) | SIGMAR1KDM5AKDM4CPHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318938-B2 | Trans-fused chromenoisoquinolines synthesis and methods for use | PURDUE RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-20090030025-A1 | TRANS-FUSED CHROMENOISOQUINOLINES SYNTHESIS AND METHODS FOR USE | PURDUE RESEARCH FOUNDATION (US) | 2009-01-29 | — | — | US | disclosed |
| EP-2010541-A2 | TRANS-FUSED CHROMENOISOQUINOLINES, SYNTHESIS AND METHODS FOR USE | Purdue Research Foundation (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1480647-B1 | MONO-ESTER AND ASYMMETRICALLY SUBSTITUTED DI-ESTER PRO-DRUGS OF THE DOPAMINE D1 RECEPTOR AGONISTS | DARPHARMA INC (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080119504-A1 | NEW APORPHINE ESTERS AND THEIR USE IN THERAPY | AXON BIOCHEMICALS B.V. (NL) | 2008-05-22 | — | — | US | disclosed |
| US-7332503-B2 | Aporphine esters and their use in therapy | AXON BIOCHEMICALS B.V. (NL) | 2008-02-19 | — | — | US | disclosed |
| WO-2007098462-A2 | TRANS-FUSED CHROMENOISOQUINOLINES, SYNTHESIS AND METHODS FOR USE | PURDUE RESEARCH FOUNDATION (US) | 2007-08-30 | — | — | WO | disclosed |
| US-7238705-B2 | Aporphine esters and their use in therapy | AXON BIOCHEMICALS B.V. (NL) | 2007-07-03 | — | — | US | disclosed |
| US-7220754-B2 | Mono-ester and asymmetrically substatuted di-ester pro-drugs of dopamide D1 receptor agonists | DARPHARMA, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| CN-1242991-C | Aporphine esters and their therapeutic use | AXON BIOCHEMICALS BV (NL) | 2006-02-22 | — | — | CN | disclosed |
| EP-1480647-A4 | MONO-ESTER AND ASYMMETRICALLY SUBSTITUTED DI-ESTER PRO-DRUGS OF THE DOPAMINE D1 RECEPTOR AGONISTS | DARPHARMA INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050143408-A1 | Aporphine esters and their use in therapy | AXON BIOCHEMICALS B.V. (NL) | 2005-06-30 | — | — | US | disclosed |
| US-20050096469-A1 | Mono-ester and asymmetrically substatuted di-ester pro-drugs of dopamide d1 receptor agonists | AXON BIOCHEMICALS B.V. (NL) | 2005-05-05 | — | — | US | disclosed |
| EP-1480647-A1 | MONO-ESTER AND ASYMMETRICALLY SUBSTITUTED DI-ESTER PRO-DRUGS OF THE DOPAMINE D1 RECEPTOR AGONISTS | Darpharma, INC. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040018956-A1 | Aporphine esters and their use in therapy | AXON BIOCHEMICALS B.V. (NL) | 2004-01-29 | — | — | US | disclosed |
| CN-1447792-A | Aporphine esters and their use in therapy | AXON BIOCHEMICALS BV (NL) | 2003-10-08 | — | — | CN | disclosed |
| WO-2003070245-A1 | MONO-ESTER AND ASYMMETRICALLY SUBSTITUTED DI-ESTER PRO-DRUGS OF THE DOPAMINE D1 RECEPTOR AGONISTS | DARPHARMA, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-1309553-A1 | NEW APORPHINE ESTERS AND THEIR USE IN THERAPY | Axon Biochemicals B.V. (NL) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002014279-A1 | NEW APORPHINE ESTERS AND THEIR USE IN THERAPY | AXON BIOCHEMICALS B.V. (NL) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143408-A1 | Aporphine esters and their use in therapy | PRLHR, LPXN, NPSR1 | SIGMAR1 86/4885KDM5A 4828/4885KDM4C 4843/4885 |
| US-20090030025-A1 | TRANS-FUSED CHROMENOISOQUINOLINES SYNTHESIS AND METHODS FOR USE | SLC6A3, HTR3B, SLC18A2 | SIGMAR1 247/4885KDM5A 4588/4885KDM4C 3740/4885 |
| US-20040018956-A1 | Aporphine esters and their use in therapy | PRLHR, LPXN, NPSR1 | SIGMAR1 86/4885KDM5A 4828/4885KDM4C 4843/4885 |
| US-20050096469-A1 | Mono-ester and asymmetrically substatuted di-ester pro-drugs of dopamide d1 receptor agonists | DRD2, DRD1, DRD4 | SIGMAR1 41/4885KDM5A 2817/4885KDM4C 3091/4885 |
| US-20080119504-A1 | NEW APORPHINE ESTERS AND THEIR USE IN THERAPY | PRLHR, LPXN, HTR1A | SIGMAR1 61/4885KDM5A 4759/4885KDM4C 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.